Search results
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC...
Napa Valley Register· 3 days agoPharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today that ...
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic...
Morningstar· 4 days ago(Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam. “The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers ...
Brokers Offer Predictions for Unity Biotechnology, Inc.’s FY2024 Earnings (NASDAQ:UBX)
ETF DAILY NEWS· 6 days agoUnity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Unity Biotechnology in a note issued to investors ...
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By
Insider Monkey via Yahoo Finance· 6 days agoIn this article, we will be taking a look at the 12 cheap foods with anti-aging properties that...
Saffron and sight: Study explores longer-term effects
Nutraingredients.com· 3 days agoAccording to a recent study published in BMJ Open Ophthalmology, 12 months of saffron...
Local women with low vision gather to share experiences, advances in tech
telegraphherald.com· 5 days agoA group of nearly 20 women who either have low vision or are a friend or caregiver of someone with...
Skye Bioscience (SKYE) versus Its Rivals Critical Survey
ETF DAILY NEWS· 5 days agoSkye Bioscience (NASDAQ:SKYE – Get Free Report) is one of 960 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare ...
Apellis Pharmaceuticals, Inc. Expected to Earn Q2 2025 Earnings of $0.23 Per Share (NASDAQ:APLS)
ETF DAILY NEWS· 2 days agoApellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Zacks Research upped their Q2 2025 EPS estimates for Apellis Pharmaceuticals in a report issued on Tuesday, April 23rd. Zacks Research ...
Mirae Asset Global Investments Co. Ltd. Reduces Holdings in REGENXBIO Inc. (NASDAQ:RGNX)
ETF DAILY NEWS· 5 days agoMirae Asset Global Investments Co. Ltd. trimmed its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 54.7% in the 4th quarter, according to its most recent disclosure with ...
Dear Doctor: Possible ALS patient frustrated by request for second opinion that goes nowhere
OregonLive.com· 4 days agoROACH: My question is about amyotrophic lateral sclerosis (ALS). Nary a test was done; the neurologist looked at the electromyography (EMG) done by a neuromuscular doctor at another facility ...